CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

Music composer SS Thaman, known for his chart-topping soundtracks, has revealed his long-standing commitment to philanthropy.

Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have ...

In UBC's latest article, Krista Payne and Dara Stein discuss the use of retrospective chart review studies as a way of capturing real-world patient-level clinical, healthcare and safety data.

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

By making genetic screening mandatory before marriage, the programme aims to: • Identify Genetic Risks Early: Detect inherited conditions such as sickle cell anemia, thalassemia, and other ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An essential factor in distinguishing thalassemia phenotypes is transfusion dependence. While beta-thalassemia major ...

The company has made significant strides in the commercialization of Casgevy for sickle cell disease and transfusion-dependent β-thalassemia, with partner Vertex activating a substantial number ...

The company has just one product on the market, Casgevy, which treats transfusion-dependent beta-thalassemia and sickle cell disease, two rare blood disorders. Casgevy has been on the market for a ...